ABSTRACT
Malignant hyperthermia manifests as a rapid and sustained rise in temperature in response to pharmacological triggering agents, e.g. inhalational anesthetics and the muscle relaxant suxamethonium. Other clinical signs include an increase in end-tidal CO₂, increased O₂ consumption, as well as tachycardia, and if untreated a malignant hyperthermia episode can result in death. The metabolic changes are caused by dysregulation of skeletal muscle Ca²⁺ homeostasis, resulting from a defective ryanodine receptor Ca²⁺ channel, which resides in the sarcoplasmic reticulum and controls the flux of Ca²⁺ ions from intracellular stores to the cytoplasm. Most genetic variants associated with susceptibility to malignant hyperthermia occur in the RYR1 gene encoding the ryanodine receptor type 1. While malignant hyperthermia susceptibility can be diagnosed by in vitro contracture testing of skeletal muscle biopsy tissue, it is advantageous to use DNA testing. Currently only 35 of over 400 potential variants in RYR1 have been classed as functionally causative of malignant hyperthermia and thus can be used for DNA diagnostic tests. Here we describe functional analysis of 2 RYR1 variants (c. 7042_7044delCAG, p.Glu2348Δ and c.641C>T, p. Thr214Met) that occur in the same malignant hyperthermia susceptible family. The p.Glu2348Δ deletion, causes hypersensitivity to ryanodine receptor agonists using in vitro analysis of cloned human RYR1 cDNA expressed in HEK293T cells, while the Thr214Met substitution, does not appear to significantly alter sensitivity to agonist in the same system. We suggest that the c. 7042_7044delCAG, p.Glu2348Δ RYR1 variant could be added to the list of diagnostic mutations for susceptibility to malignant hyperthermia.

INTRODUCTION
Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder that predisposes susceptible individuals to an acute increase in cytosolic [Ca²⁺] during general anesthesia using volatile anesthetics or depolarizing muscle relaxants. In addition, several studies suggest that MH-susceptibility is commonly associated with elevated resting cytosolic [Ca²⁺]. Acutely elevated cytosolic [Ca²⁺] results in a hypermetabolic state, characterized by an increase in end-tidal CO₂, increased O₂ consumption, and tachycardia. Hyperthermia results with core temperatures increasing by 1°C every 5 minutes. Uncontrolled hypermetabolism leads to respiratory and metabolic acidosis, rhabdomyolysis, hyperkalemia, widespread organ failure and death if untreated by the drug dantrolene.

The majority (50–70%) of individuals affected with MH have gain-of-function variants in the RYR1 gene, encoding the skeletal muscle ryanodine receptor, while ~1% have variants in the α1s subunit of the dihydropyridine receptor (DHPR) gene (CACNA1S). The DHPR is a multi-subunit voltage-dependent Ca²⁺ channel, which resides in the T-tubule membrane. Upon response to membrane depolarization it causes the RyR1 tetramer to open due to physical contact between the 2 channels. As a result Ca²⁺ is released into the cytoplasm from the sarcoplasmic reticulum (SR) stores, triggering muscle contraction as well as a range of other physiological and pathological changes.
of other metabolic responses. This process is known as excitation-contraction coupling. \(^{11}\) \(\text{Ca}^{2+}\) is returned to the sarcoplasmic reticulum by a \(\text{Ca}^{2+}\)-ATPase (SERCA). \(^{12}\) This tightly controlled balance of intracellular \(\text{Ca}^{2+}\) concentrations is dysregulated in an MH crisis.

Because MH is a life-threatening disorder, susceptibility should ideally be determined prior to general anesthesia, such that non-triggering agents can be used. MH susceptibility in New Zealand is normally determined by \textit{in vitro} contracture test (IVCT) using skeletal muscle biopsy tissue following the European Malignant Hyperthermia Group (EMHG) protocol. \(^{13}\) DNA-based diagnostic tests were introduced in New Zealand in 1998, \(^{14}\) to augment the IVCT and, while these are now becoming more accepted, \(^{15,16}\) they do not replace the IVCT for many individuals because of the genetic heterogeneity of MH. \(^{17-19}\) In addition, DNA-based diagnosis for MH susceptibility can be carried out only in families with known mutations that have been functionally characterized. \(^{18}\) This constraint, while appropriate, represents a major hurdle to being able to offer DNA testing on a more general basis. In addition, an MHN diagnosis cannot be made upon a DNA test alone, rather an IVCT is recommended where a DNA test is negative for a familial mutation. \(^{20}\)

Here we report functional analysis of 2 \textit{RYR1} variants, \textit{c.641C>T}, \textit{p.Thr214Met} and \textit{c.7042_7044delCAG}, \textit{p.Glu2348} in the same family, both of which have been linked to MH previously. \(^{21,22}\) We constructed human \textit{RYR1} cDNAs with either variant as well as a construct containing both. Functional analysis was carried out in transiently transfected HEK293T cells using 4-CmC as a specific RyR1 agonist and fura-2 as the fluorescent \(\text{Ca}^{2+}\) indicator. The \textit{c.641C>T}, \textit{p.Thr214Met} RyR1 variant did not appear to affect \(\text{Ca}^{2+}\) release in this system, but the \textit{c.7042_7044delCAG}, \textit{p.Glu2348} deletion resulted in a hypersensitive channel suggesting that it is likely to be causative of MH.

\section*{Results}

\textit{In vitro contracture tests}

Muscle biopsies and \textit{in vitro} contracture tests were carried out as described in methods for the proband and his mother (II:1 and I:1 respectively in Fig. 1). The proband was diagnosed MHS and the mother MHN. Thus far the father (I:2, Fig. 1) has declined IVCT testing. The IVCT results are shown in Table 1.

\begin{table}[h]
\centering
\caption{IVCT values.}
\begin{tabular}{|c|c|c|c|}
\hline
Patient & Contracture (g) at 2\% halothane & Contracture (g) at 2 mM caffeine & MH Status \\
\hline
I:1 & 0.4 & 0.2 & MHN \\
II:1 & 5.2 & 3.0 & MHS \\
\hline
\end{tabular}
\end{table}

\begin{figure}[h]
\centering
\includegraphics{figure1.png}
\caption{Pedigree diagram showing inheritance of RyR1 variants from each parent and MH status where known.}
\end{figure}

\section*{DNA sequencing and variant screening}

The entire \textit{RYR1} gene of the proband (Fig. 1, II:1) and his mother (Fig. 1, I:1) as well as the \textit{CACNA1S} gene and 48 others with potential roles in skeletal muscle \(\text{Ca}^{2+}\) handling were screened using the HaloPlex\textsuperscript{TM} target enrichment system followed by next generation sequencing as described in methods. All exons of the \textit{CACNA1S} and \textit{RYR1} genes were represented in the data set with an average coverage between 30 and 156 with the exception of \textit{RYR1} exon 91, which was completed using Sanger sequencing. The proband carries both the \textit{c.641C>T}, \textit{p.Thr214Met} and \textit{c.7042_7044delCAG}, \textit{p.Glu2348} RyR1 variants. Neither variant is listed in the Exome Variant Server. The mother carries the \textit{c.641C>T}, \textit{p.Thr214Met} \textit{RYR1} variant only. No other rare (minor allele frequency of < 0.1\%) variants in any other genes in this dataset were identified for either subject. The \textit{c.7042_7044delCAG}, \textit{p.Glu2348} RyR1 variant was detected in genomic DNA from the father (Fig. 1, I:2) using kinetic PCR followed by high resolution amplicon melting (HRM). \(^{23}\) Neither variant was detected by HRM screening of a panel representing 150 MHN patients.

\section*{Expression of recombinant RyR1 in HEK293T cells}

RyR1 expression in transiently transfected HEK293T cells was determined by western blotting to confirm approximately equal amounts of recombinant protein was produced for each construct (Fig. 2). Alpha-tubulin (~50 kDa) was used as a loading control. No RyR1...
protein was detected in the vector-only (pcDNA3.1+) negative control.

Immunofluorescence was used to confirm correct co-localization of the recombinant RyR1 proteins with the endoplasmic reticulum (ER) marker protein disulfide isomerase, (PDI, Fig. 3). No RyR1 was detected in HEK293T cells transfected with empty pcDNA3.1+ vector, used as a negative control.

**Ca²⁺ release assays**

The activities of variant RyR1 channels expressed in the ER of HEK293T cells were compared with the activity of the wild-type (WT) RyR1 channels using Ca²⁺ release assays under identical conditions. The increase in cytoplasmic calcium was measured after the addition of incremental doses of the RyR1 agonist 4-CmC to the cells and then calculated as a percentage of total Ca²⁺ release (Fig. 4). The RyR1 variants c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp were used as positive controls as the former has been validated as an MH-causative mutation by the EMHG (https://emhg.org/genetics/mutations-in-ryr1/) and the latter was shown to be causative using our system. Both had significantly increased sensitivities to 4-CmC compared to WT as expected (Table 2). The p.ΔGlu2348 RyR1 variant was hypersensitive compared to WT when stimulated with 4-CmC as with both agonists the curve was shifted to the left (Fig. 4, dark blue trace). A similar result was observed for the double RyR1 variant p.Thr214Met/ p.ΔGlu2348. EC50 values are presented in Table 2. Resting cytosolic calcium was significantly different to empty vector for the p. Arg2452Trp and p.ΔGlu2348 RyR1 constructs only. All other constructs including the double variant, p. Thr214Met/p.ΔGlu2348 were similar to the vector only control (Table 3).

**Discussion**

The objective of the current study was to determine the effect of 2 RyR1 variants on the function of the skeletal muscle Ca²⁺ channel using a heterologous system in vitro. Both variants occur in the proband, having been inherited from each parent (Fig. 1). As positive controls for hypersensitivity, the previously-characterized MH-causative c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp RyR1 mutations were also tested under the same conditions. Under our experimental conditions RyR1 containing the c.641C>T, p. Thr214Met variant cannot be functionally distinguished from the WT RyR1 channel, although the different shaped concentration response curves for 4-CmC suggest some abnormality may exist. While the mother who carries this variant was diagnosed as MHN by IVCT, 3 families in the United Kingdom show concordance between this variant and disease and/or IVCT phenotype. The IVCT results for the mother (Fig. 1, I:1 and Table 1) are borderline between MHS and MHN so the MHN diagnosis could be a false negative given that the IVCT has been determined to have a specificity of only 93.6% and sensitivity of 99%. False negative IVCT results could be due to the testing laboratory-defined cut-off values or to variable penetrance of mutations detected. In support of the MHN diagnosis however, a retrospective study of 329 patients diagnosed MHN in New Zealand, showed no evidence of any adverse reaction in subsequent anesthesia using triggering agents. In addition it is important to note that the transfected HEK293T cells express only exogenous RyR1 with none of the other proteins known to be part of the skeletal muscle triad, the functional unit of excitation-contraction coupling. The activities of variant RyR1 channels expressed in the ER of HEK293T cells were compared with the activity of the wild-type (WT) RyR1 channels using Ca²⁺ release assays under identical conditions. The increase in cytoplasmic calcium was measured after the addition of incremental doses of the RyR1 agonist 4-CmC to the cells and then calculated as a percentage of total Ca²⁺ release (Fig. 4). The RyR1 variants c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp were used as positive controls as the former has been validated as an MH-causative mutation by the EMHG (https://emhg.org/genetics/mutations-in-ryr1/) and the latter was shown to be causative using our system. Both had significantly increased sensitivities to 4-CmC compared to WT as expected (Table 2). The p.ΔGlu2348 RyR1 variant was hypersensitive compared to WT when stimulated with 4-CmC as with both agonists the curve was shifted to the left (Fig. 4, dark blue trace). A similar result was observed for the double RyR1 variant p.Thr214Met/ p.ΔGlu2348. EC50 values are presented in Table 2. Resting cytosolic calcium was significantly different to empty vector for the p. Arg2452Trp and p.ΔGlu2348 RyR1 constructs only. All other constructs including the double variant, p. Thr214Met/p.ΔGlu2348 were similar to the vector only control (Table 3).

**Discussion**

The objective of the current study was to determine the effect of 2 RyR1 variants on the function of the skeletal muscle Ca²⁺ channel using a heterologous system in vitro. Both variants occur in the proband, having been inherited from each parent (Fig. 1). As positive controls for hypersensitivity, the previously-characterized MH-causative c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp RyR1 mutations were also tested under the same conditions. Under our experimental conditions RyR1 containing the c.641C>T, p. Thr214Met variant cannot be functionally distinguished from the WT RyR1 channel, although the different shaped concentration response curves for 4-CmC suggest some abnormality may exist. While the mother who carries this variant was diagnosed as MHN by IVCT, 3 families in the United Kingdom show concordance between this variant and disease and/or IVCT phenotype. The IVCT results for the mother (Fig. 1, I:1 and Table 1) are borderline between MHS and MHN so the MHN diagnosis could be a false negative given that the IVCT has been determined to have a specificity of only 93.6% and sensitivity of 99%. False negative IVCT results could be due to the testing laboratory-defined cut-off values or to variable penetrance of mutations detected. In support of the MHN diagnosis however, a retrospective study of 329 patients diagnosed MHN in New Zealand, showed no evidence of any adverse reaction in subsequent anesthesia using triggering agents. In addition it is important to note that the transfected HEK293T cells express only exogenous RyR1 with none of the other proteins known to be part of the skeletal muscle triad, the functional unit of excitation-contraction coupling. The activities of variant RyR1 channels expressed in the ER of HEK293T cells were compared with the activity of the wild-type (WT) RyR1 channels using Ca²⁺ release assays under identical conditions. The increase in cytoplasmic calcium was measured after the addition of incremental doses of the RyR1 agonist 4-CmC to the cells and then calculated as a percentage of total Ca²⁺ release (Fig. 4). The RyR1 variants c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp were used as positive controls as the former has been validated as an MH-causative mutation by the EMHG (https://emhg.org/genetics/mutations-in-ryr1/) and the latter was shown to be causative using our system. Both had significantly increased sensitivities to 4-CmC compared to WT as expected (Table 2). The p.ΔGlu2348 RyR1 variant was hypersensitive compared to WT when stimulated with 4-CmC as with both agonists the curve was shifted to the left (Fig. 4, dark blue trace). A similar result was observed for the double RyR1 variant p.Thr214Met/ p.ΔGlu2348. EC50 values are presented in Table 2. Resting cytosolic calcium was significantly different to empty vector for the p. Arg2452Trp and p.ΔGlu2348 RyR1 constructs only. All other constructs including the double variant, p. Thr214Met/p.ΔGlu2348 were similar to the vector only control (Table 3).

**Discussion**

The objective of the current study was to determine the effect of 2 RyR1 variants on the function of the skeletal muscle Ca²⁺ channel using a heterologous system in vitro. Both variants occur in the proband, having been inherited from each parent (Fig. 1). As positive controls for hypersensitivity, the previously-characterized MH-causative c.742G>A, p.Gly248Arg and c.7354C>T, p.Arg2452Trp RyR1 mutations were also tested under the same conditions. Under our experimental conditions RyR1 containing the c.641C>T, p. Thr214Met variant cannot be functionally distinguished from the WT RyR1 channel, although the different shaped concentration response curves for 4-CmC suggest some abnormality may exist. While the mother who carries this variant was diagnosed as MHN by IVCT, 3 families in the United Kingdom show concordance between this variant and disease and/or IVCT phenotype. The IVCT results for the mother (Fig. 1, I:1 and Table 1) are borderline between MHS and MHN so the MHN diagnosis could be a false negative given that the IVCT has been determined to have a specificity of only 93.6% and sensitivity of 99%. False negative IVCT results could be due to the testing laboratory-defined cut-off values or to variable penetrance of mutations detected. In support of the MHN diagnosis however, a retrospective study of 329 patients diagnosed MHN in New Zealand, showed no evidence of any adverse reaction in subsequent anesthesia using triggering agents. In addition it is important to note that the transfected HEK293T cells express only exogenous RyR1 with none of the other proteins known to be part of the skeletal muscle triad, the functional unit of excitation-contraction coupling.
Figure 3. Co-localization of RyR1 with the endoplasmic reticulum. Immunofluorescence of transiently transfected HEK293T cells with RyR1 cDNA. Variants are indicated by their amino acid change. Primary antibodies that specifically recognize RyR1 (34C) and PDI as well as fluorescently-labeled secondary antibodies FITC (green) and TRITC (red) were used to visualize RyR1 and PDI respectively, while nuclei were visualised by staining the cells with DAPI (blue). Cells were examined by confocal fluorescence microscopy at a magnification of 1260 X; the scale bar in each merged image represents a length of 20 microns.
contraction coupling, being present. This variant may therefore have a RyR1 function that cannot be investigated in our system due to the lack of protein-protein interactions with partners of the excitation-contraction system. The c.641C>T, p.Thr214Met residue is located within a β-sheet in the β-trefoil B domain in the structurally-characterized N-terminal domain encompassing residues 1-559 of rabbit RyR1. This region forms 3 domains predicted to interact through a hydrophilic interface. The Thr214 residue does not appear to be part of the direct domain interaction but is located in a linker region between 2 domains, which is buried in the 3-dimensional structure. Methionine is an aliphatic residue however, as well as being larger than the hydrophilic threonine, which may lead to structural alteration of the folded protein or localized misfolding. Although our functional data suggest the c.641C>T, p.Thr214Met variant is unlikely to be a variant altering Ca2+ release from the SR/ER, the concordance between this variant and MHS in 3 other families, as well as the limitations of the HEK293T assay system indicate that currently we cannot rule out a functional consequence of this variant for RyR1.

On the other hand the c.7042_7044delCAG, p.DGlu2348 variant results in a hypersensitive channel, which suggests that it is likely to cause MH. While the clinical signs of MH for the proband (Fig. 1, II:1) were minor, the IVCT data (Table 1) indicated very strong contractions and a clear MHS diagnosis. DNA testing has shown that the father (Fig. 1, I:2) carries the c.7042_7044delCAG, p.DGlu2348 RyR1, and while MH status has not been confirmed by IVCT, he should be considered at high risk. This RYR1 variant has been associated with MHS in at least one other unrelated family, also associated with very strong contracture tension. No predictions however, can be made about any mechanistic effect that this deletion would have on structure or function of the channel. While a near-atomic resolution cryo EM structure predicts this residue to be situated in a helical domain, the resolution was sufficient to trace the backbone structure only.

It has been suggested that MH can be caused by hyperactive RyR1 channels resulting in a higher than normal Ca2+ release under stimulating conditions.
causing a crisis event. Our results support this conclusion for the c. 7042_7044delCAG, p.Glu2348 variant. As RyR1 with the p.Arg2452Trp and p.Glu2348 variants demonstrated significantly higher resting calcium levels, these variants may result in a functionally “leaky” channel. The p.Arg2452 residue is thought to lie at a domain interface in the cytoplasmic domain of the RyR1 tetramer and perturbation of predicted surface interactions by the introduction of the bulky hydrophobic tryptophan in place of the positively charged arginine residue could have functional consequences for channel stability in the unstimulated state. These observations support the “leaky” channel mechanism suggested as an alternative mechanism leading to an MH crisis. They also support previous work with synthetic peptides representing this region, which indicate that interdomain interactions are likely to be responsible for opening and closing the tetrameric channel.

While calcium release was similar for the RyR1 p.Glu2348 and the p.Thr214Met/p.Glu2348 variants, the p.Thr214Met/p.Glu2348 variant did not appear to result in a “leaky” channel. This suggests that the p.Thr214Met variant may in some way compensate for the p.Glu2348 variant in the resting state. It should be noted however, that these 2 variants are in the same RyR1 monomer in this recombinant system, rather than in different monomers as would be the case in the proband. Even though co-transfection of different RYR1 constructs has been performed in previous studies, the exact assembly of the tetrameric RyR1 channel with the different monomers cannot be predicted.

As the c. 7042_7044delCAG, p.Glu2348 RyR1 variant has been identified in at least 2 unrelated families and is a conserved residue, as well as conferring hypersensitivity to a specific RyR1 agonist in a heterologous system, it should be classed as an MH causative mutation. A substitution at this position (c.7043 A>G, p.Glu2348Gly) also segregates with MHS in a UK family, supporting the potential importance of this residue in RyR1 function.

Patients and methods

Case history

A 7 y old, 22 kg child with no family history presented for squint correction in 1999. He had a gas induction with Sevoflurane in oxygen, and was then intubated with 15 mg Rocuronium. Once intubated, he was noted to have a high end-tidal CO₂ of 67 mmHg. This resolved with minute ventilation of 2.5 L/min bringing end-tidal CO₂ down to 42 mmHg. After induction, the volatile agent was changed to isoflurane for maintenance of anesthesia. Approximately 20 minutes into the case, the end-tidal CO₂ again rose from 42 to 58 mmHg, and he developed a mild tachycardia. A rectal temperature was taken which was 37°C and he felt warm to the touch. He was given analgesia with fentanyl 40 μg, and then morphine 2 mg, and the tachycardia resolved. He was given antiemetic prophylaxis with 2 mg of Ondansetron. The anesthetist was concerned that these subtle changes (tachycardia and raised end-tidal CO₂) may represent MH, so he stopped administering the volatile agent, went onto high fresh gas flows and maintained anesthesia with a propofol infusion. At the closure of surgery the child was extubated and taken to recovery. Creatine kinase was 221 U/L; the upper limit of normal at the laboratory was 220 U/L. His temperature never rose above 37°C degrees and he was not given dantrolene. He was observed overnight in the intensive care unit, and no other signs of MH were noted. He was referred for in vitro contracture testing at Palmerston North hospital and a diagnosis of MHS was confirmed.

Regulatory authority approvals

This study has been approved by the Central Regional Ethics Committee, Ministry of Health, Wellington, New Zealand (MWH/03/04/018) and the Massey University Genetic Technology Committee (GMO 05/ MU/01 and GMO 00/MU/60) acting as an Institutional Biological Safety Committee for the Environmental Protection Authority, Wellington, New Zealand.

In vitro contracture tests

Muscle biopsies were obtained and in vitro contracture testing (IVCT) was performed at Palmerston North hospital using the standard diagnostic procedure for MH-susceptibility according to the European Malignant Hyperthermia group (EMHG) protocol and local laboratory control data. Briefly this involves exposure of muscle bundles to incremental amounts of halothane and caffeine, while measuring contracture tension in g. A diagnosis of MHS is
made if the responses to both halothane and caffeine are above the threshold of 0.4 g using 2% halothane and 0.2 g using 2 mM caffeine. An MHN diagnosis is made if the response is below threshold for both agents. If the response is above threshold for only one of the agents the diagnosis is MHS(h) or MHS(c) for halothane and caffeine respectively. All patients tested MHS, MHS(h) or MHS(c) would be classed as susceptible to MH and be given non-triggering anesthesia.13

**DNA Sequencing**

Genomic DNA was isolated from patient blood samples (3 mL) using the Promega Wizard™ genomic DNA extraction kit according to the manufacturer’s instructions. This was followed by quantification using the Quant-iT™ dsDNA high-sensitivity DNA assay kit (Life Technologies, Q-33120) following the manufacturer’s instructions and diluted in TE buffer to a final concentration of 5 ng/μL. The HaloPlex™ Target Enrichment system (Agilent Technologies, G9901C) was used to prepare custom libraries from the genomic DNA representing 50 genes with known or potential association with MH. Purified amplified libraries were quantified using the High Sensitivity DNA kit (Agilent Technologies, 5067-4626) with the 2100 Bioanalyzer. Libraries were pooled in equimolar (400 pmol) amounts prior to massively parallel sequencing on the Illumina MiSEQ platform by the Next Generation Sequencing Facility, University of Leeds and the Leeds Teaching Hospitals NHS Trust, St James University Hospital Leeds, UK or New Zealand Genomic Limited at Massey University, Palmerston North, New Zealand. Sequences were aligned using Agilent SureCall™ software against hg19 using the default parameters. Exon 91 of RYR1 was amplified in 3 segments using Dream Taq™ DNA polymerase (Fermentas, FMTEP0702), the products purified using ExoSAP-IT® (Affymetrix, 78200) and then 10 ng of each PCR product was mixed with 4 pmol of the appropriate primer and Sanger sequencing was carried out by Macrogen (Korea). The PCR and sequencing primers are available on request. Sequences were aligned to the RYR1 cDNA (NM_000540.2) using the web based tool Emboss through EMBoss (http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html).

**High resolution amplicon melting**

Primers (Table 4) for high resolution amplicon melting (HRM) assays were designed for the c.641C>T, p. Thr214Met and p.ΔGlu2348 RyR1 variants using the Light Cycler™ Primer Design software version 2.0 (Roche). cDNA and protein numbering are according to NM_000540.2 and NP_000531.2, respectively. Reactions contained 3 mM MgCl2, 0.3 or 0.2 mM of each primer for the p.Thr214Met and p.ΔGlu2348 variants respectively and, 5 μL of 2x LC480 HRM master mix (Roche, 04909631001) and 25 ng of genomic DNA in a total volume of 10 μL. PCR amplification was carried out on a Roche Light Cycler 480 using a touch-down protocol as follows: 95°C for 10 minutes (ramp rate 4.40°C/sec), followed by 40 cycles of 95°C (ramp rate 4.40°C/sec) for 10 sec, 65°C (ramp rate 2.20°C/sec) with secondary target of 58°C (step size 0.5°C) for 10 sec and 72°C (ramp rate 4.40°C/min) for 4 sec. Single acquisition of data was at the 72°C amplification step. The melt program was as follows: 95°C for 1 min (ramp rate 4.40°C/sec), 40°C for 1 min (ramp rate 1.5°C/sec), 76°C for 1 sec (ramp rate 4.40°C/sec) followed by continuous acquisition at 92°C with a ramp rate of 0.02°C/sec and 25 acquisitions per °C. The final cooling cycle had a 40°C target, 30 sec hold and a ramp rate of 1.5°C/sec. Alleles were called using GeneScan software version 1.5.1.

| Table 4. Oligonucleotide primers.  
| --- | --- | --- |
| Primer name | Sequence | Purpose |
| Thr214Met F_SD | GAAGAGGGCTTCGTGTGGAGTGCACTCCTC | Site-directed mutagenesis |
| Thr214Met R_SD | GAGGACGTCACCTCCACGAAACCCCTCTC | Site-directed mutagenesis |
| ΔGlu2348 F_SD | CCCCCGACCTTGGGCTCTCCTCCTCCAAGCCGTGGC | Site-directed mutagenesis |
| ΔGlu2348 R_SD | CAACCTCCCTGCTCCT | Site-directed mutagenesis |
| Thr214Met F_HRM | CAACCTCCCTGCTCCT | HRM |
| Thr214Met R_HRM | CGCTGGTACATCTACGTCA | HRM |
| ΔGlu2348 F_HRM | CCAGGCAGAGCGTGGGAG | HRM |
| ΔGlu2348 R_HRM | CGGATGAGAGCGCGAG | HRM |
Site directed mutagenesis and cloning

Mutagenesis was carried out by PCR-amplification of ~70 ng of plasmid DNA containing approximately 2.7 kb of the relevant subclones of human RYR1 cDNA (NM_000540.2) using the 2x Kapa HiFi HotStart ReadyMix (Kapa Biosystems, KR0370) diluted 4x. Complementary mutagenetic primer pairs (Table 4) were sourced from Integrated DNA Technologies and used for QuickChange™ (Stratagene) mutagenesis. Cycling conditions were 95°C for 5 min; 98°C for 2 minutes; 57°C for 30 seconds; 72°C at 1 min/kb; 72°C for 5 minutes; steps 2-3 were repeated 18 times. The PCR products were digested with 20 units of restriction endonuclease DpnI (New England BioLabs, R0176S) and buffer according to the manufacturer’s instructions.

The full-length RYR1 cDNA containing the specified variants was generated in 3 sequential cloning steps by standard methods.40 Constructs were confirmed by Sanger DNA sequencing using a capillary ABI3730 Genetic Analyzer with BigDye™ Terminator v3.1 chemistry at the Massey Genome Service, Palmerston North, New Zealand.

Cell culture and transient transfection

HEK293T cells for all applications were grown in DMEM (Dulbecco’s Modified Eagle’s Medium, Sigma D7777), 10% FBS (fetal bovine serum, Gibco 10091-148), 0.5% penicillin/streptomycin (Life Technologies, 15140-122) at 37°C, 5% CO2 in a humidified atmosphere. For immunoblotting cells were grown to 90% confluence in T25 flasks using 8 mL of medium and for immunofluorescence, to 50% confluence in a 4 chambered slide containing 1 mL medium. For Ca2+ release assays, cells were grown to 80% confluence in UV transparent 96 well plates with each well containing 200 μL medium. Medium was replaced one hour prior to transfection once the correct level of confluence was achieved.

For immunoblotting HEK293T cells were transiently transfected with RYR1 cDNA or empty pcDNA3.1+ (Invitrogen, V790-20) plasmids, using 6 μg plasmid DNA and 24 μL FuGENE HD (Promega, E2311) to a total volume of 300 μL with unsupplemented DMEM, which was added directly to the 8 mL of medium in T25 flasks. After 48 hours, the medium was replaced and growth continued for another 24 hours. Protein extracts were prepared after washing cells with PBS and resuspending in 150 μL of lysis buffer [0.1 M Tris HCl, pH 7.8, 0.5% triton X-100, 20 μL 7x Complete Mini EDTA-free protease inhibitor (Roche, 1183617001)]. Insoluble proteins were separated via centrifugation at 13,000 rcf at 4°C. Supernatant was stored at −80°C with limited freeze-thaw cycles.

For immunofluorescence, transient transfection was carried out using 1 μg DNA, 3 μL Fugene 6 (Roche, 11814443001) and DMEM without supplements, to a final volume of 50 μL. Fresh complete medium was replaced after 48 hours and growth continued for another 24 hours prior to processing.

For Ca2+ release assays, HEK293T cells (with 100 μL complete medium per well) were transfected with 100 ng DNA, 1.2 μL Fugene HD in unsupplemented DMEM to a final volume of 14 μL. Cells were incubated overnight prior to the addition of an extra 100 μL complete DMEM. After 24 hours incubation, media was replaced with 200 μL complete DMEM. After a further 24 hours incubation the transfected cells were used in calcium release assays.

Immunoblotting

Protein extracts (~270 μg) were resolved by SDS-PAGE (4% stacking gel and 7.5% separating gel) for 2 hours at 120 V using a Mini PROTEAN electrophoresis system (Bio-Rad). Proteins were transferred to a PVDF membrane at 70 mA for 20 hours at 4°C. After transfer, the membrane was blocked in 5 mL 5% skim milk in TBST (0.05 M Tris HCl, 0.15 mM NaCl, 0.1% tween 20) for 3 hours at room temperature with gentle agitation. The membrane was cut to separate the 565 kDa RyR1 from the 50 kDa α-tubulin loading control. The membrane containing higher molecular weight proteins was incubated overnight at 4°C in 5 mL mouse 34C primary antibody (Sigma, R129) diluted 1:1000 in 2.5% skim milk in TBST with gentle shaking. The membrane containing the lower molecular weight proteins was incubated overnight at 4°C in 5 mL mouse α-tubulin primary antibody (Sigma, T8203) diluted 1:5000 in 2.5% skim milk in TBST with gentle shaking. Both membranes were then incubated at room temperature for 20 minutes with shaking prior to 3 washes in TBST. Both membranes were incubated in 5 mL anti-mouse horse radish peroxidase conjugated secondary antibody (Sigma, A9044) diluted...
1:5000 in 2.5% skim milk in TBST for one hour at room temperature. The membranes were washed 3 times in TBST prior to detection.

Chemiluminescence blotting substrate (Roche, 11500694001) was prepared by mixing 3 mL luminescence substrate solution A with 30 μL starting solution B. The substrate was applied to the membranes just prior to visualization of the proteins by the exposure to X-ray film.

**Immunofluorescence**

After an initial washing step in 500 μL of PBS (0.14 M NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄ pH 7.2) cells were fixed in 500 μL 2% paraformaldehyde in PBS for 15 minutes at room temperature and washed 3 times in PBS and then permeabilised using 0.1% Triton X-100 in PBS for 5 minutes. After washing 3 times in PBS, the cells were blocked in 1 mL 5% bovine serum albumin, 0.5% Tween-20 in PBS with gentle shaking at 4°C with gentle shaking in 1 mL primary antibody solution [mouse 34C diluted 1:1000 or rabbit anti protein disulphide isomerase, PDI (Sigma, p7496) diluted 1:1000 in PBS]. The cells were then incubated at room temperature for 20 minutes, and washed 3 times in PBS. Finally, the cells were incubated at room temperature with gentle shaking for 1 hour in 500 μL secondary antibody solution [fluorescein isothiocyanate (FITC) conjugated goat anti-mouse secondary antibody (Jackson immuno research, 15095003) diluted 1:200 in 50 μL PBS, for RyR1 or tetramethylrhodamine (TRITC) conjugated goat anti-rabbit secondary antibody (Jackson immuno research, 11025003) diluted 1:200 in 500 μL for PDI and then washed 3 times in PBS. A cover slip was mounted using 7 μL ProLong Gold AntiFade mounting solution containing DAPI (Invitrogen, p-36931) to stain the nucleus. The slides were incubated overnight before being visualised using a Leica SP5 DM6000B Scanning Confocal Microscope at 1260 × magnification at the Maassey Microscopy and Imaging Center.

**Measurement of Ca²⁺ release**

Transiently-transfected HEK293T cells were incubated in 100 μL balanced salt solution, BSS (140 mM NaCl, 2.8 mM KCl, 1 mM MgCl₂, 10 mM glucose, 10 mM HEPES, pH 7.25) containing 2 mM CaCl₂, 2 μM fura2-AM (Molecular Probes, F-1221) and 0.01% pluronic F-127 (Sigma P2443) per well for one hour at 37°C in the dark. The cells were washed once with 100 μL BSS plus Ca²⁺ and once in 100 μL Ca²⁺-free BSS buffer (containing 2 mM EGTA). Activation of the RyR1 using 4-CmC (Sigma, C55402) as the agonist was measured by the change in the fluorescence emission ratio at 510 nm, when excited at 340 nm and 380 nm, using an Olympus X181 fluorescence microscope. Each well was assayed after establishing a fluorescence ratio baseline for using 100 μL Ca²⁺-free balanced salt solution before adding 100 μL Ca²⁺-free balanced salt solution containing 4-CmC. The baseline of the fluorescence ratio was used to estimate integrity of the ER membrane and potential leakage due the presence of RyR1 variant proteins. The final concentrations of 4-CmC used were: 200, 300, 400, 600, 800 and 1000 μM.

**Statistical analysis**

The amount of Ca²⁺ release at each concentration of 4-CmC was normalized to account for any differences in cell density for each assay and calculated as a percentage of the total Ca²⁺ released with 1000 μM 4-CmC. A minimum of 8 analytical replicates were carried out for each construct, the results were pooled and a sigmoidal curve fitted for each data set using OriginLab Origin 8 software. Results are presented as the mean ± standard error of the mean (SEM) for each value of 4-CmC used. The concentration of agonist required for half maximal fluorescence change (EC50) was calculated from curves fitted to individual replicates and represented as mean ± SEM. The statistical significance of each EC50 value was determined using the unpaired Student’s t-test with OriginLab Origin 8 software and represented as a p-value with respect to WT and a Bonferroni correction was carried out to confirm statistical significance.

**Abbreviations**

| Abbreviation | Description                              |
|--------------|------------------------------------------|
| BSS          | Balanced salt solution                   |
| CACNA1S      | Gene encoding the α1s subunit of the dihydropyridine receptor |
| cDNA         | complementary DNA                        |
| 4-CmC        | 4-chloro-m-cresol                        |
Disclosure of potential conflicts of interest

No potential conflicts of interest are disclosed.

Acknowledgments

We would like to thank Professor Phil Hopkins (Leeds MH Unit, St. James University Hospital) for the targeted capture panel, as well as the HaloPlex™ enrichment and next generation sequencing that was carried out while the corresponding author was a visitor to his laboratory and Mrs Lili Rhodes (Institute of Fundamental Sciences, Massey University) for technical support.

Funding

This study was supported by the Massey University Research Fund for consumables and the Australian and New Zealand College of Anesthetists (grant number 15/011) for salary for AS.

References

[1] MacLennan DH, Chen SR. The role of the calcium release channel of skeletal muscle sarcoplasmic reticulum in malignant hyperthermia. Ann N Y Acad Sci 1993; 707:294-304; PMID:9137560; http://dx.doi.org/10.1111/j.1749-6632.1993.tb38060.x
[2] Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011; 107:48-56; PMID:21624965; http://dx.doi.org/10.1093/bja/aer132
[3] Vukcevic M, Broman M, Islander G, Bodelsson M, Rannels-Twetman E, Muller CR, Treves S. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease. Anesth Analg 2010:111:185-90; PMID:2042353
[4] Yang T, Esteve E, Pessah IN, Molinski TF, Allen PD, Lopez JR. Elevated resting [Ca2+]i in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am J Physiol Cell Physiol 2007;292:C1591-8 Epub 2006 Dec 20; PMID:17182726; http://dx.doi.org/10.1152/ajpcell.00133.2006
[5] Eltit JM, Bannister RA, Moua O, Altamirano F, Hopkins PM, Pessah IN, Molinski TF, Lopez JR, Beam KG, Allen PD. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor. Proc Natl Acad Sci U S A 2012; 109:7923-8; PMID:22547813; http://dx.doi.org/10.1073/pnas.1119207109
[6] Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18:632-52; PMID:11553240; http://dx.doi.org/10.1097/00003643-200110000-00002
[7] Lopez JR, Allen P, Alamo L, Ryan JF, Jones DE, Sreter F. Dantrolene prevents the malignant hyperthermic syndrome by reducing free intracellular calcium concentration in skeletal muscle of susceptible swine. Cell Calcium 1987; 8:385-96; PMID:3427616; http://dx.doi.org/10.1016/0143-4160(87)90013-3
[8] Broman M, Gehrig A, Islander G, Bodelsson M, Rannels-Twetman E, Ruffert H, Muller CR. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Br J Anaesth 2009; 102:642-9; PMID:19346234; http://dx.doi.org/10.1093/bja/aep061
[9] Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant
hyperthermia and central core disease. Hum Mutat 2006; 27:977-89; PMID:16917943; http://dx.doi.org/10.1002/humu.20356

[10] Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59:178-84; PMID:11260227; http://dx.doi.org/10.1034/j.1399-0004.2001.590306.x

[11] Rebbeck RT, Willemsse H, Groom L, Casarotto MG, Board PG, Beard NA, Dirksen RT, Duhunty AF. Regions of ryanodine receptors that influence activation by the dihydropyridine receptor beta1a subunit. Skelet Muscle 2015; 5:23; PMID:26203350; http://dx.doi.org/10.1186/s13395-015-0049-3

[12] Gilchrist JS, Palahniuk C, Abrenica B, Rampersad P, Mutawe M, Cook T. RyR1/SERCA1 cross-talk regulation of calcium transport in heavy sarcoplasmic reticulum vesicles. Can J Physiol Pharmacol 2003; 81:220-33; PMID:12733821; http://dx.doi.org/10.1139/y03-035

[13] Hopkins PM, Ruffert H, Snoeck MM, Girard T, Glahn D, Pollock N, Ruffert H, Snoeck MM, Girard T, Glahn D, Pollock N. Malignant hyperthermia: Clinical utility gene card for molecular genetic detection of susceptibility to malignant hyperthermia. Anesthesiology 2004; 100:1076-80; PMID:15114203; http://dx.doi.org/10.1097/00000542-200405000-00008

[14] Stowell KM, Brown R, James D, Couchman K, Hodges TV, MacLennan DH. Caffeine and halothane sensitivity of the RyR1 cation of the Arg1086His mutation in the alpha subunit of the RyR1 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Cell Calcium 2014; 56:1950201; http://dx.doi.org/10.1086/671528

[15] Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing, JAMA 2005; 293:2918-24; PMID:15956637; http://dx.doi.org/10.1001/jama.293.23.2918

[16] Rosenberg H, Rueffert H. Clinical utility gene card for: malignant hyperthermia. Eur J Hum Genet 2001; 9:1139-44; PMID:11303177; http://dx.doi.org/10.1046/j.1568-1063.2001.01114.x

[17] Robinson RL, Anetseder MJ, Brancadoro V, van Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003; 11:342-8; PMID:12700608; http://dx.doi.org/10.1038/sj.ejhg.5200964

[18] Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86:283-7; PMID:11573677; http://dx.doi.org/10.1093/bja/86.2.283

[19] Robinson R, Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Markham AF, Stewart AD, West SP, Ellis FR. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet 1998; 35:196-201; PMID:9541102; http://dx.doi.org/10.1136/jmg.35.3.196

[20] Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004; 100:1076-80; PMID:15114203; http://dx.doi.org/10.1097/00000542-200405000-00008

[21] Fiszer D, Shaw MA, Fisher NA, Carr IM, Gupta PK, Watkins EJ, Roiz de Sa D, Kim JH, Hopkins PM. Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness. Anesthesiology 2015; 122:1033-46; PMID:25658027; http://dx.doi.org/10.1097/ALN.0000000000000610

[22] Sambuughin N, McWilliams S, de Bantel A, Sivakumar K, Nelson TE. Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001; 69:204-8; PMID:11389482; http://dx.doi.org/10.1086/362127

[23] Grievink H, Stowell KM. Identification of ryanodine receptor 1 single-nucleotide polymorphisms by high-resolution melting using the LightCycler 480 System. Anal Biochem 2008; 374:396-404 Epub 2007 Nov 21; PMID:18082125; http://dx.doi.org/10.1016/j.ab.2007.11.019

[24] Roesl C, Sato K, Schiemann AH, Pollock N, Stowell KM. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility. Cell Calcium 2014; 56:1950201; http://dx.doi.org/10.1086/671528

[25] Tong J, Oyamada H, Demaurex N, Grinstein S, McCarthy TV, MacLennan DH. Caffeine and halothane sensitivity of intracelular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997; 272:26332-26339; PMID:9334205; http://dx.doi.org/10.1074/jbc.272.42.26332

[26] Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauer V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41:955-66; PMID:9311391; http://dx.doi.org/10.1111/j.1399-6576.1997.tb04820.x

[27] Ording H. Diagnosis of susceptibility to malignant hyperthermia in man. Br J Anaesth 1988; 60:287-302; PMID:3279989; http://dx.doi.org/10.1093/bja/60.3.287

[28] Pollock N, Langton EE, Stowell KM, Bulger TF. Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents. Anaesth Intensive Care 2011; 39:887-94; PMID:21970134

[29] Ording H, Islander G, Bendixen D, Ranklev-Tweetman E. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. Anesth Analg 2000; 91:452-7; PMID:10910867; http://dx.doi.org/10.1213/00000539-200008000-00042

[30] Tung CC, Lobo PA, Kimlicka L, Van Petegem F. The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature 2010; 468:585-8; PMID:21048710; http://dx.doi.org/10.1038/nature09471
[31] Sambuughin N, McWilliams S, de Bantel A, Sivakumar K, Nelson TE. Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001; 69:204-8 Epub 2001 May 29; PMID: 11389482; http://dx.doi.org/10.1086/321270

[32] Yan Z, Bai XC, Yan C, Wu J, Li Z, Xie T, Peng W, Yin CC, Li X, Scheres, SH, et al. Structure of the rabbit ryanodine receptor RyR1 at near-atomic resolution. Nature 2015; 517:50-5; PMID:25517095; http://dx.doi.org/10.1038/nature14063

[33] Tong J, McCarthy TV, MacLennan DH. Measurement of resting cytosolic Ca\textsuperscript{2+} concentrations and Ca\textsuperscript{2+} store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca\textsuperscript{2+} release channels. J Biol Chem 1999; 274:693-702; PMID:9873004; http://dx.doi.org/10.1074/jbc.274.2.693

[34] Ikemoto N, Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci 2002; 7:d671-83; PMID:11861212; http://dx.doi.org/10.2741/ikemoto

[35] Avila G, Dirksen RT. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 2001; 118:277-90; PMID:11524458; http://dx.doi.org/10.1085/jgp.118.3.277

[36] Murayama T, Oba T, Hara H, Wakebe K, Ikemoto N, Ogawa Y. Postulated role of interdomain interaction between regions 1 and 2 within type 1 ryanodine receptor in the pathogenesis of porcine malignant hyperthermia. Biochem J 2007; 402:349-57; PMID:17107340; http://dx.doi.org/10.1042/Bj20061040

[37] Yamamoto T, El-Hayek R, Ikemoto N. Postulated role of interdomain interaction within the ryanodine receptor in Ca\textsuperscript{2+} channel regulation. J Biol Chem 2000; 275:11618-25; PMID:10766778; http://dx.doi.org/10.1074/jbc.275.16.11618

[38] Kraeva N, Heytens L, Jungbluth H, Treves S, Voermans N, Kamsteeg E, Ceuterick-de Groote C, Baets J, Riazi S. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy. Neuromuscul Disord 2015; 25:567-76; PMID:25958340; http://dx.doi.org/10.1016/j.nmd.2015.04.007

[39] Shepherd S, Ellis F, Halsall J, Hopkins P, Robinson R. RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene. J Med Genet 2004; 41:e33; PMID:14985404; http://dx.doi.org/10.1136/jmg.2003.014274

[40] Sato K, Pollock N, Stowell KM. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Anesthesiology 2010; 112:1350-4; PMID:20461000; http://dx.doi.org/10.1097/ALN.0b013e3181d69283